Epidermal Growth Factor (EGF) (Active) Protein

Details for Product No. ABIN413180, Supplier: Log in to see
Protein Name
  • HOMG4
  • URG
  • AI790464
  • CEGF
  • epidermal growth factor
  • pro-epidermal growth factor
  • EGF
  • egf
  • CpipJ_CPIJ020278
  • Egf
  • LOC100008808
Origin
Human
81
42
26
7
2
1
Source
Escherichia coli (E. coli)
109
8
6
4
4
2
2
2
1
1
1
Protein Type
Recombinant
Biological Activity
Active
Application
High Pressure Liquid Chromatography (HPLC), SDS-PAGE (SDS)
Options
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Get this product for free

It's quick and easy to submit your validation proposal. I want to validate this product

Learn more

Available images

Characteristics Molecule Information: Human EGF is a 6.2 kDa recombinant protein
Purity ≥98 % by SDS-PAGE
≥98 % by HPLC
Endotoxin Level <0.1 ng/μg
ProductDetails: Biological Activity Comment The ED₅₀ of human EGF is determined by the dose-dependent stimulation of BALB/c 3T3 cells is 5.92-10.06 ng/ml.
Background Human epidermal growth factor (EGF) is also known as HOMG4 and URG, and is a growth factor that plays an important role in the regulation of cell growth, proliferation, and differentiation by binding to its receptor EGFR. Epidermal growth factor can be found in human platelets, macrophages, urine, saliva, milk, and plasma. EGF is the founding member of the EGF-family of proteins. Members of this protein family have highly similar structural and functional characteristics. All family members contain one or more repeats of the conserved amino acid sequence. The biological effects of salivary EGF include healing of oral and gastroesophageal ulcers, inhibition of gastric acid secretion, stimulation of DNA synthesis as well as mucosal protection from intraluminal injurious factors such as gastric acid, bile acids, pepsin, and trypsin and to physical, chemical and bacterial agents. Because of the increased risk of cancer by EGF, inhibiting it decreases cancer risk. Recombinant human EGF is a 6.2 kDa protein containing 53 amino acid residues. This recombinant human EGF has an N-terminal His-tag preceding the 53 amino acid sequence (MW = 8.5 kDa)

Alternative Names: Urogastrone, URG, EGF, epidermal growth factor
UniProt Q6QBS2
Research Area Cancer, Growth Factors
Pathways NF-kappaB Signaling, RTK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Regulation of Carbohydrate Metabolic Process, Hepatitis C, Protein targeting to Nucleus, Interaction of EGFR with phospholipase C-gamma, Thromboxane A2 Receptor Signaling, EGFR Downregulation
Application Notes Optimal working dilution should be determined by the investigator.
Restrictions For Research Use only
Format Lyophilized
Reconstitution Reconstitute the human EGF in H₂O to a concentration of 0.1-1 mg/mL. This solution can then be diluted into other aqueous buffers and stored at 4 °C for 1 week or -20 °C for future use.
Buffer EGF protein is lyophilized with no additives
Handling Advice Centrifuge the vial prior to opening.
Storage -20 °C
Expiry Date 12 months
Supplier Images
 image for Epidermal Growth Factor (EGF) (Active) Protein (ABIN413180) Epidermal Growth Factor (EGF) (Active) protein
Product cited in: Wang, Qian, Li, Pan, Njunge, Dong, Yang: "Evaluation of emulsion electrospun polycaprolactone/hyaluronan/epidermal growth factor nanofibrous scaffolds for wound healing." in: Journal of biomaterials applications, 2015 (PubMed).

An, Gip, Kim, Wu, Park, McVaugh, Schaffer, Bertozzi, Lebrilla: "Extensive determination of glycan heterogeneity reveals an unusual abundance of high mannose glycans in enriched plasma membranes of human embryonic stem cells." in: Molecular & cellular proteomics : MCP, Vol. 11, Issue 4, pp. M111.010660, 2012 (PubMed).